Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
25 hedge funds and large institutions have $820K invested in Aevi Genomic Medicine Inc in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 4 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
9% more capital invested
Capital invested by funds: $752K → $820K (+$68.5K)
14% less funds holding
Funds holding: 29 → 25 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$78.8K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$26.3K |
| 4 |
VF
Virtu Financial
New York
|
+$5.84K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$15K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$6K |
| 3 |
AMCA
Arthur M. Cohen & Associates
Northbrook,
Illinois
|
-$5.03K |
| 4 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$2.81K |
| 5 |
KCPG
Kavar Capital Partners Group
Leawood,
Kansas
|
-$1K |
GNMX Hedge Fund Activity: Q3 2019 in Review
25 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q3 2019, worth a combined $820K — up 9.1% from $752K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GNMX and 0 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $78.8K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $15K sold.
- 25 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q3 2019, down from 29 in Q2 2019.
- Funds reported $820K of Aevi Genomic Medicine Inc stock for Q3 2019, up 9.1% quarter-over-quarter.
- 0 funds opened new Aevi Genomic Medicine Inc positions in Q3 2019 and 4 closed out, a net change of -4 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q3 2019 was Renaissance Technologies, an estimated $78.8K added.
- The largest Aevi Genomic Medicine Inc seller in Q3 2019 was Acadian Asset Management, an estimated $15K sold.
Based on aggregated 13F filings for Q3 2019.